densitas densityai

by Densitas  · Based in Canada → — Transforming the Mammography Enterprise with AI Solutions
Oncology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact for pricing
Regulatory Status Disclosed

Overview

Densitas densityai™ is a deep learning algorithm that provides automated, standardized, and reproducible breast density assessments from mammograms. It is a core component of the broader intelliMammo™ platform by Densitas Inc., which offers comprehensive AI solutions for breast cancer screening.

The tool uniquely utilizes two distinct deep learning models to decouple breast density assessment into quantitative percent mammographic density (0%-100%) and qualitative descriptive categories (A, B, C, D), aligning with both the ACR BI-RADS® 4th and 5th Edition density scales. By eliminating the subjectivity and lack of reliability associated with visual assessment, densityai™ establishes standardization across entire health systems, supporting compliance with federal and regional breast density notification laws.

Densitas densityai™ seamlessly integrates into existing reporting and PACS workflows, boosting efficiency and facilitating retrospective analyses. It processes routinely archived ‘for presentation’ images and generates results that are available on-demand at the point of care for radiological technologists and radiologists, and retrospectively for clinic and health system administrators through an advanced analytics platform.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Automated and standardized breast density assessments
  • Aligns with ACR BI-RADSu00ae Atlas 4th and 5th Edition density scales
  • Eliminates subjectivity and improves reproducibility of breast density assessment
  • Supports compliance with federal and regional breast density notification laws
  • Integrates into existing reporting and PACS workflows
  • Identifies higher-risk women for supplemental screening
  • Utilizes deep learning models for analysis
  • Processes routinely archived 'for presentation' mammograms
  • Generates Secondary Capture (SC) and Structured Report (SR) objects
  • Provides quantitative percent mammographic density and qualitative descriptive categories

Use Cases

  • Standardized breast density classification at point-of-care
  • Ensuring compliance with breast density reporting requirements
  • Informing referral pathways for supplemental imaging
  • Risk stratification of patients for tailored follow-up screening protocols
  • Improving workflow efficiency and reducing unnecessary callbacks
  • Supporting breast cancer screening trials and research

What Physicians Need to Know

Key Capabilities
Provides automated, standardized, and reproducible breast density assessments aligned with ACR BI-RADS Atlas 5th edition (quantitative percent and qualitative 4-category A, B, C, D) using deep learning algorithms. It is part of the broader intelliMammou00ae platform, which includes tools for mammography quality and risk assessment.
Clinical Utility
Eliminates subjectivity and improves reproducibility in breast density assessments, standardizing results across health systems. It helps identify higher-risk women for supplemental screening and supports compliance with breast density notification laws. The assessments can be integrated into breast cancer risk models.
Integration Options
Designed for seamless integration into existing reporting and PACS workflows, processing standard DICOM images. It integrates with platforms like Nuance AI Marketplace (PowerScribe One/360), Blackford Platform, Ikonopedia, TeraRecon's EnvoyAI, and Three Palm Software's WorkstationOne. The solution offers vendor-neutral interoperability.
Compliance Status
FDA-cleared and supports compliance with FDA MQSA EQUIP and breast density reporting requirements. It provides an ACR BI-RADS Atlas 5th Edition breast density category, serving as adjunctive information, not a diagnostic aid. Available in the US, Canada, Europe, UK, and Australia.
Pricing Model
Not publicly disclosed; likely a B2B licensing model, with a focus on cost-effectiveness and operational efficiency for healthcare systems.
User Experience
Automates subjective and time-consuming manual breast density assessments, offering 'zero-click implementation' for radiologists by deeply embedding results into reporting workflows and automatically populating reports. It provides rapid, reproducible, and standardized results at the point of care.
Implementation Complexity
Considered to have relatively low implementation complexity due to seamless integration with existing PACS and reporting workflows, processing routinely archived images, and offering vendor-neutral interoperability.
Evidence Base
The deep learning algorithm is rigorously validated for face-validity and shows almost perfect agreement with expert radiologist consensus. Models are developed, tested on multi-site, multi-vendor datasets, and externally validated, demonstrating generalizability across FFDM and DBT modalities. It has been clinically validated for breast cancer risk association and used in major trials like DIMASOS 2 in Germany. Published studies support its efficacy.
Physician Tip

Densitas densityai offers a robust solution for standardizing breast density assessment, which is crucial for consistent patient care and compliance with evolving notification laws. Leverage its automated, reproducible results to streamline reporting, reduce subjective variability, and inform personalized screening pathways, especially for high-risk patients. The seamless integration into existing workflows minimizes disruption, allowing radiologists to focus more on complex interpretive tasks. Remember it's an adjunctive tool, not a diagnostic aid, and should complement, not replace, comprehensive clinical evaluation.

Densitas densityai is designed for broad compatibility, integrating directly with PACS, RIS, and major reporting systems like Nuance PowerScribe. Its vendor-neutral approach and ability to process standard DICOM images facilitate straightforward integration into diverse imaging environments. Compatibility with AI marketplaces (e.g., Nuance, Blackford) further enhances its accessibility and interoperability within a broader AI ecosystem.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Contact for pricing
DeploymentHybrid (on-premise integration with PACS/reporting systems, cloud-based analytics platform)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Densitas densityai™ received FDA 510(k) clearance (K192973) on February 19, 2020, for providing breast density assessments in accordance with the American College of Radiology's BI-RADS 5th edition density classification scale.
Integrations
EHR Not specified
Specialties Oncology, Radiology

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate densitas densityai

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

PR Newswire
Densitas Joins Nuance AI Marketplace for Diagnostic Imaging To Deliver Breast Density Assessment
Densitas Inc. announced that its FDA-cleared densitasu00ae densityaiu2122 breast density assessment software will be available on the Nuanceu00ae AI Marketplace, providing access to over 70 percent of radiologists across connected healthcare facilities in the USA. The software delivers automated, standardized, and reproducible breast density assessments from standard DICOM clinical use images.
2019-10
AuntMinnie
Densitas and Blackford expand AI partnership | AuntMinnie
Densitas and Blackford have expanded their AI partnership, with Densitas's densityAI being a second application to be integrated onto the Blackford Platform.
2022-05
Canada Newswire
Densitas Inc. Wins Major Procurement of Its AI-Powered Breast Density Software for DIMASOS Breast Screening Trial
Densitas Inc. won a procurement for its densitas densityaiu2122 software to be deployed in up to twenty-four breast cancer screening clinics in Germany for the DIMASOS 2 Trial. The software will provide breast density measurements at the point of care to identify women for supplemental breast cancer screening.
2019-09
Imaging Technology News
Densitas Wins Major Procurement of Breast Density Software for DIMASOS Breast Screening Trial | Imaging Technology News
Densitas Inc. announced a procurement win for its densitas densityai software, which will be implemented in up to 24 breast cancer screening clinics across Germany as part of the DIMASOS 2 Trial. The software aims to provide automated, standardized, and reproducible breast density assessments.
2019-09
Canadian Healthcare Technology
PEI uses Densitas breast density software province-wide | Canadian Healthcare Technology
Prince Edward Island (PEI) has integrated Densitas Inc.'s Health Canada-licensed automated breast density software, densitas densityaiu2122, into its breast screening program. This integration ensures that every woman receiving a screening mammogram in PEI will be notified of her breast density through the software's AI-powered algorithm.
2020-02
PMC (PubMed Central)
Computational healthcare: Present and future perspectives (Review) - PMC
This review article lists 'densitas densityai' by Densitas, Inc. as an AI-based application for diagnosis in radiology, approved in 2020.
2020
PMC (PubMed Central)
Theranostics and artificial intelligence: new frontiers in personalized medicine
This article mentions Densitas Densityai (Densitas, Inc.) as an FDA-approved AI-based radiological software system for the BI-RADS breast density category using mammography, with approval in 2020 (K192973).
2024-03
AJR (American Journal of Roentgenology)
Artificial Intelligence (AI) for Screening Mammography, From the AJR Special Series on AI Applications
This article notes that 'densitas densityai' received FDA approval on February 19, 2020, for breast density assessment.
2024-02

Videos

Product demos, reviews, and walkthroughs for densitas densityai.

View all on YouTube

Frequently Asked Questions

Densitas densityai seamlessly integrates into existing reporting and PACS workflows, processing routinely archived 'for presentation' mammography images. It automatically provides standardized breast density assessments aligned with ACR BI-RADS Atlas 5th edition guidelines, delivering results directly into the reporting system to boost efficiency and facilitate retrospective analyses.
Densitas densityai is a U.S. Food and Drug Administration (FDA)-cleared software application and complies with FDA density reporting requirements. It provides breast density assessments in alignment with the ACR BI-RADS Atlas 5th Edition breast composition classification guidelines, supporting compliance with federal and regional breast density notification laws.
While Densitas densityai significantly reduces subjectivity and standardizes breast density assessment, it is important to remember it is an adjunctive tool and not a diagnostic aid. Its accuracy relies on the quality of the input mammographic images, and it provides information to aid interpreting physicians rather than replacing their clinical judgment.
Densitas densityai eliminates the subjectivity and lack of reproducibility associated with visual breast density assessments, establishing standardization across health systems. Its deep learning algorithm provides reliable and reproducible results that have demonstrated almost perfect agreement with expert radiologist consensus, leading to more consistent patient risk stratification and referral pathways.
Yes, other AI solutions exist, such as iCAD's Density Assessment tool. Densitas densityai differentiates itself by uniquely using two distinct deep learning models that decouple quantitative percent mammographic density and qualitative BI-RADS categories, and by its ability to process prior 'for presentation' mammograms from a wide range of scanner vendors for seamless PACS integration.
Specific pricing models for Densitas densityai are not publicly disclosed in the provided information. Physicians or practices interested in obtaining pricing details should directly contact Densitas or their authorized distributors for a personalized quote and information on licensing options.
While specific security protocols are not detailed, as an FDA-cleared medical device integrated into healthcare workflows, Densitas densityai is designed to operate within established healthcare IT infrastructures. This implies adherence to industry standards for data security and patient privacy, consistent with regulations like HIPAA, when handling protected health information.

Related Tools

FAITH project (Fatigue Therapy – AI-supported Diagnosis and Therapy of Tumour-associated Fatigue Syndrome)
Fimo Health GmbH (Consortium Leader)
Mental & Behavioral Health AI
The FAITH project is developing an AI-based solution for the diagnosis and therapy of tumor-associated fatigue syndrome in cancer patients. It uses wearable sensors, a smartphone app, and artificial intelligence to provide individualized therapy recommendations and monitor mental health.
AI-based support system for skin cancer diagnostics
German Cancer Research Center (DKFZ)
Clinical Decision Support & Reference
Scientists at the German Cancer Research Center have developed an AI-based support system for skin cancer diagnostics that explains its decisions, increasing doctors' confidence in both the AI and their own diagnoses.
eyonis® LCS
Median Technologies
Oncology AI
eyonis® LCS is an FDA 510(k) cleared AI/machine learning-powered software for the detection and diagnosis of lung cancer, helping clinicians detect and characterize suspicious parenchymal pulmonary nodules earlier on low-dose CT scans.
Lumea Digital Pathology
Lumea
Clinical Decision Support & Reference
Lumea is a specialty-specific digital pathology platform that covers the entire diagnostic workflow, from biopsy to final report, and integrates AI tools from partners like Paige and Mindpeak.
Azra AI
Azra AI
Clinical Decision Support & Reference
Azra AI is an AI platform that swiftly analyzes, identifies, and classifies cancer patients, triaging those needing therapy and follow-up to enhance oncology care. It is deployed at more than 1,500 sites and integrated with leading EHRs.
Custom subscription model
Trial Library
Trial Library
Drug Discovery & Research
Trial Library's AI-native platform is embedded in community oncology practices to identify eligible patients for oncology clinical trials. It integrates clinical trials into routine care, activating providers, identifying eligible patients, and navigating them through the trial lifecycle across health systems, biopharma, and payers.

See all Oncology AI tools →

More from Densitas

DM-Density
Densitas
Oncology AI
Densitas' DM-Density, now densitas densityai™, is an FDA-cleared AI software for automated and standardized breast density assessment from digital mammograms, aligning with ACR BI-RADS® Atlas 5th Edition.
Contact for pricing

View company profile →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.